|
1
|
Stupp R, Mason WP, van den Bent MJ, et al:
Radiotherapy plus concomitant and adjuvant temozolomide for
glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wang B, Han L, Chen R, et al:
Downregulation of LRIG2 expression by RNA interference inhibits
glioblastoma cell (GL15) growth, causes cell cycle redistribution,
increases cell apoptosis and enhances cell adhesion and invasion in
vitro. Cancer Biol Ther. 8:1018–1023. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Guo D, Holmlund C, Henriksson R and Hedman
H: The LRIG gene family has three vertebrate paralogs widely
expressed in human and mouse tissues and a homolog in Ascidiacea.
Genomics. 84:157–165. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nilsson J, Vallbo C, Guo D, et al:
Cloning, characterization, and expression of human LIG1. Biochem
Biophys Res Commun. 284:1155–1161. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ishii H and Furukawa Y: Alterations of
common chromosome fragile sites in hematopoietic malignancies. Int
J Hematol. 79:238–242. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Martinez A, Walker RA, Shaw JA, Dearing
SJ, Maher ER and Latif F: Chromosome 3p allele loss in early
invasive breast cancer: detailed mapping and association with
clinicopathological features. Mol Pathol. 54:300–306. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hedman H, Nilsson J, Guo D and Henriksson
R: Is LRIG1 a tumour suppressor gene at chromosome 3p14.3? Acta
Oncol. 41:352–354. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Thomasson M, Hedman H, Guo D, Ljungberg B
and Henriksson R: LRIG1 and epidermal growth factor receptor in
renal cell carcinoma: a quantitative RT-PCR and immunohistochemical
analysis. Br J Cancer. 89:1285–1289. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yang WM, Yan ZJ, Ye ZQ and Guo DS: LRIG1,
a candidate tumour-suppressor gene in human bladder cancer cell
line BIU87. BJU Int. 98:898–902. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tanemura A, Nagasawa T, Inui S and Itami
S: LRIG-1 provides a novel prognostic predictor in squamous cell
carcinoma of the skin: immunohistochemical analysis for 38 cases.
Dermatol Surg. 31:423–430. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gur G, Rubin C, Katz M, et al: LRIG1
restricts growth factor signaling by enhancing receptor
ubiquitylation and degradation. EMBO J. 23:3270–3281. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lindstrom AK, Ekman K, Stendahl U, et al:
LRIG1 and squamous epithelial uterine cervical cancer: correlation
to prognosis, other tumor markers, sex steroid hormones, and
smoking. Int J Gynecol Cancer. 18:312–317. 2008. View Article : Google Scholar
|
|
13
|
Miller JK, Shattuck DL, Ingalla EQ, et al:
Suppression of the negative regulator LRIG1 contributes to ErbB2
overexpression in breast cancer. Cancer Res. 68:8286–8294. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li F, Ye ZQ, Guo DS and Yang WM:
Suppression of bladder cancer cell tumorigenicity in an athymic
mouse model by adenoviral vector-mediated transfer of LRIG1. Oncol
Rep. 26:439–446. 2011.PubMed/NCBI
|
|
15
|
Welsh JB, Sapinoso LM, Su AI, et al:
Analysis of gene expression identifies candidate markers and
pharmacological targets in prostate cancer. Cancer Res.
61:5974–5978. 2001.PubMed/NCBI
|
|
16
|
Lapointe J, Li C, Higgins JP, et al: Gene
expression profiling identifies clinically relevant subtypes of
prostate cancer. Proc Natl Acad Sci USA. 101:811–816. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hedman H and Henriksson R: LRIG inhibitors
of growth factor signalling - double-edged swords in human cancer?
Eur J Cancer. 43:676–682. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ye F, Gao Q, Xu T, et al: Upregulation of
LRIG1 suppresses malignant glioma cell growth by attenuating EGFR
activity. J Neurooncol. 94:183–194. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Guo D, Nilsson J, Haapasalo H, et al:
Perinuclear leucine-rich repeats and immunoglobulin-like domain
proteins (LRIG1-3) as prognostic indicators in astrocytic tumors.
Acta Neuropathol. 111:238–246. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yuan B, Latek R, Hossbach M, Tuschl T and
Lewitter F: siRNA Selection Server: an automated siRNA
oligonucleotide prediction server. Nucleic Acids Res. 32:W130–W134.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tuschl T: Expanding small RNA
interference. Nat Biotechnol. 20:446–448. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Golding SE, Morgan RN, Adams BR, Hawkins
AJ, Povirk LF and Valerie K: Pro-survival AKT and ERK signaling
from EGFR and mutant EGFRvIII enhances DNA double-strand break
repair in human glioma cells. Cancer Biol Ther. 8:730–738. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rao SK, Edwards J, Joshi AD, Siu IM and
Riggins GJ: A survey of glioblastoma genomic amplifications and
deletions. J Neurooncol. 96:169–179. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yeh KY, Chang JW, Li YY, Wang CH and Wang
HM: Tumor growth inhibition of metastatic nasopharyngeal carcinoma
cell lines by low dose of arsenic trioxide via alteration of cell
cycle progression and induction of apoptosis. Head Neck.
33:734–742. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chandele A, Prasad V, Jagtap JC, Shukla R
and Shastry PR: Upregulation of survivin in G2/M cells and
inhibition of caspase 9 activity enhances resistance in
staurosporine-induced apoptosis. Neoplasia. 6:29–40. 2004.
View Article : Google Scholar
|
|
26
|
Tate MC and Aghi MK: Biology of
angiogenesis and invasion in glioma. Neurotherapeutics. 6:447–457.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wild-Bode C, Weller M and Wick W:
Molecular determinants of glioma cell migration and invasion. J
Neurosurg. 94:978–984. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rao JS: Molecular mechanisms of glioma
invasiveness: the role of proteases. Nat Rev Cancer. 3:489–501.
2003. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kapoor GS and O’Rourke DM: Receptor
tyrosine kinase signaling in gliomagenesis: pathobiology and
therapeutic approaches. Cancer Biol Ther. 2:330–342. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Fu Y, Zhang Q, Kang C, et al: Inhibitory
effects of adenovirus mediated Akt1 and PIK3R1 shRNA on the growth
of malignant tumor cells in vitro and in vivo. Cancer Biol Ther.
8:1002–1009. 2009. View Article : Google Scholar
|
|
31
|
Laederich MB, Funes-Duran M, Yen L, et al:
The leucine-rich repeat protein LRIG1 is a negative regulator of
ErbB family receptor tyrosine kinases. J Biol Chem.
279:47050–47056. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Shindo H, Tani E, Matsumuto T, Hashimoto T
and Furuyama J: Stabilization of c-myc protein in human glioma
cells. Acta Neuropathol. 86:345–352. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang J, Wang H, Li Z, et al: c-Myc is
required for maintenance of glioma cancer stem cells. PLoS One.
3:e37692008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Jensen KB and Watt FM: Single-cell
expression profiling of human epidermal stem and transit-amplifying
cells: LRIG1 is a regulator of stem cell quiescence. Proc Natl Acad
Sci USA. 103:11958–11963. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Dang CV: c-Myc target genes involved in
cell growth, apoptosis, and metabolism. Mol Cell Biol. 19:1–11.
1999.PubMed/NCBI
|
